Grants for City or township governments - Consumer Protection

The ConnectALL Initiative's Municipal Infrastructure Program (MIP) is designed to foster the development of open-access, publicly owned, and/or controlled last-mile fiber broadband infrastructure. This initiative aims to deliver reliable high-speed internet services to homes, businesses, and community anchor institutions throughout New York State. The program's mission aligns directly with the New York State Urban Development Corporation d/b/a Empire State Development ("ESD") objectives to promote a vigorous and growing state economy, encourage business investment and job creation, and support diverse, prosperous local economies across NYS. By addressing broadband access, the MIP contributes to ESD's broader strategy of using grants and other forms of assistance to facilitate economic development and improve quality of life for residents. The target beneficiaries of the MIP include communities across New York State that are currently experiencing connectivity challenges due to a lack of affordable, high-speed internet infrastructure. Specifically, the program aims to connect homes, businesses, and community anchor institutions. The primary impact goal is to improve broadband access, thereby reducing the digital divide and enabling greater participation in the digital economy. Expected outcomes include a significant increase in the availability of reliable, high-speed internet, leading to enhanced economic opportunities, improved educational access, and better access to essential services for residents and businesses in underserved areas. The program's priorities and focuses revolve around the construction of new infrastructure or the acquisition of existing infrastructure. This includes last-mile fiber connections to address last-mile infrastructure (cabling, wires, pole replacements, radios) and drops to buildings. It also emphasizes fiber connections to Internet Exchange Points or Data Centers, including middle-mile fiber and networking equipment. A key focus is on ensuring open-access and predominantly publicly controlled infrastructure, leveraging funding from the U.S. Department of Treasury Capital Projects Fund (CPF) to achieve these objectives. The ConnectALL Initiative's strategic priorities are deeply rooted in addressing fundamental connectivity gaps across the state. The theory of change posits that by investing in publicly controlled, open-access fiber broadband infrastructure, the state can stimulate economic growth, create jobs, and foster more equitable access to information and opportunities. The expected measurable results include the deployment of new fiber optic networks, the number of homes, businesses, and community anchor institutions connected, and ultimately, an improvement in the overall broadband speed and affordability available to New Yorkers. The total funding available for this program is $228 Million, with a maximum grant size of $30 million per award, indicating a significant investment to achieve these transformative goals.

The Food and Drug Administration's (FDA), Center for Drug Evaluation and Research (CDER), Office of New Drugs (OND), is announcing this Funding Opportunity Announcement (FOA) for a Cooperative Agreement. The proposed work directly supports the U.S. FDAs stated goal of protecting public health from unacceptable risks from nitrosamine impurities in human drugs. Although significant experimental and policy/regulatory initiatives have been undertaken in this area, there remains a need for further research into and development and refinement of translational and implementable practices that will protect the public against nitrosamine risks while ensuring continued safe access to critical therapeutic drugs. The aim is to improve the safety of human drugs with potential nitrosamine impurity liabilities. In addition to the work outlined above, the award recipient will assess how best to ensure that this research and practices development continues among industry members, non-profits, and/or academic institutions once the FDA funding for this cooperative agreement ends.

Youth Service America's (YSA) "We Serve to Remember 9/11 Day of Service Grants" program is designed to empower young changemakers aged 5 to 25. This initiative directly aligns with YSA's mission of engaging youth in service and fostering active citizenship. The grants support organizations, schools, and youth changemakers in planning and implementing service activities that honor and pay tribute to those affected by 9/11. The program emphasizes youth leadership, ensuring that projects are driven by the young participants themselves, thereby developing their leadership skills and sense of community responsibility. The program's target beneficiaries are primarily youth, with a strong focus on engaging those who are not typically asked to serve and face systemic barriers to participation. This includes young people of color, youth from underserved low-income families and neighborhoods, and youth who are often beneficiaries of service rather than participants. Specific groups identified include youth in rural communities, those experiencing homelessness, youth in foster care, youth with disabilities, youth in the juvenile justice system, immigrants or refugees, youth from military families, LGBTQ+ youth, and English language learners. The impact goal is to create a more inclusive service environment and empower a diverse group of young people to contribute to their communities. A key priority of this grant program is the engagement of at least 100 youth volunteers per project, with 80% of these volunteers identifying as youth facing systemic barriers to participation. Projects must include elements to honor and pay tribute to those who lost their lives on 9/11, their families, and those who responded in service. All activities must take place on or around September 11th National Day of Service and Remembrance (September 11, 2024). This specific timing reinforces the program's focus on remembrance and national service. YSA expects to award up to 100 grants of $1,000 each. The expected outcomes include a significant increase in youth engagement in service, particularly among marginalized groups, and the successful execution of service activities that commemorate 9/11. Measurable results will include the number of grants awarded, the number of youth volunteers engaged, and the percentage of those volunteers who identify as facing systemic barriers. The program also aims to foster a sense of civic duty and historical awareness among participants. The foundation's strategic priorities are centered on youth empowerment and inclusive participation in service. YSA's theory of change posits that by providing resources and opportunities, particularly to underserved youth, they can develop leadership skills, strengthen communities, and create a lasting impact. By focusing on youth-led projects and ensuring diverse representation, YSA aims to build a generation of civically engaged individuals who are committed to addressing community needs and remembering significant historical events. Applicants must be based in the United States, with activities benefiting people in the U.S., including its territories. This geographical focus ensures that the grants support local communities across the nation. The emphasis on reaching youth who face systemic barriers aligns with a broader strategic goal of promoting equity and inclusion within the service sector, demonstrating YSA's commitment to a more representative and impactful youth service movement.

This Notice of Funding Opportunity (NOFO) invites applications for a cooperative agreement to support, manage and facilitate Public-Private Partnerships and Collaborative activities as part of the Critical Path Initiative and to support regulatory science efforts. FDA and grantees will work together to develop innovative, collaborative projects in research, education, and outreach. These projects can help foster drug product innovation to 1) support efforts to accelerate drug product development; 2) support approaches to advanced manufacturing; 3) facilitate translation of basic science discoveries into therapeutics; and 4) facilitate approaches to enhance the safety, efficacy, quality, and performance of drug products. Projects are identified by FDA. Multiple awards may be funded under this NOFO and are directly dependent on drug development priorities and subject to the availability of funding.

The Bitsie Clark Fund for Artists (The Bitsie Fund), housed at the Community Foundation for Greater New Haven, aims to support individual artists in pursuing new work and achieving specific creative and career goals. This aligns with the Foundation's broader mission to foster a thriving community by supporting local talent and development. The fund's focus is on individual artist development, rather than community development, signifying a strategic priority to invest directly in the artistic growth of residents within the Foundation's service area in Greater New Haven. In 2024, The Bitsie Fund will award two $5,000 grants, one specifically for a Black artist and another open to all eligible artists. This targeting reflects a commitment to equitable support within the artistic community and addresses potential disparities. The grant's impact goals are centered on enabling artists to tackle major artistic development goals, take risks on new directions in their work, or advance their careers. The expected outcomes include a more vibrant artistic community with empowered individual artists. The fund prioritizes individual artists at a significant point in their personal development, encouraging both established artists with a substantial body of recent work and those emerging in their field to apply. This inclusive approach to eligibility ensures a broad reach within the artist community. The focus is on supporting a wide array of creative disciplines including dance, music, theater, visual arts, design, craft, literary arts, voice, poetry, playwriting, composition, and film. Measurable results would be evidenced by artists successfully utilizing the funds for approved uses such as purchasing materials, compensating for time spent developing projects, hiring others, covering performance or touring costs, travel for proposals, renting studio space, and production expenses. Ultimately, the Bitsie Fund's theory of change posits that by directly supporting individual artists in these ways, it will contribute to their personal and professional growth, thereby enriching the cultural landscape of Greater New Haven.

This funding opportunity supports researchers in developing innovative tools that can speed up drug development and improve regulatory processes, ultimately enhancing public health by facilitating faster access to effective treatments.

Notice of Funding Opportunity Description Background The Food and Drug Administration (FDA) protects the public health by ensuring that medical products intended to be marketed in the United States are safe and effective for their intended use. FDA stakeholders are exploring innovative ways to produce scientific evidence in support of regulatory submissions, including the development of new data sources, study designs, methodologies, and technologies. FDA encourages and facilitates the use of such innovative approaches while ensuring that the scientific evidence supporting marketing approvals meet our high evidentiary standards. The Prescription Drug User Fee Act VII (PDUFA VII) commitment letter represents the product of discussions between the FDA, regulated industry, and public stakeholders, as mandated by Congress. The performance and procedural goals and other commitments specified in the PDUFA VII commitment letter apply to aspects of the human drug review program that are important for facilitating timely access to safe, effective, and innovative new medicines for patients. The commitment letter includes goals relating to the use of digital health technologies (DHTs) to support drug development and review. A DHT is a system that uses computing platforms, connectivity, software, and/or sensors, for health care and related uses. DHTs for remote data acquisition in clinical investigations can include hardware and/or software to perform one or more functions. DHTs may rely on or work with other technologies that support their operation, such as general-purpose computing platforms (e.g., smartphones) and communication networks. Among other activities relating to the use of DHTs, FDA has established a Framework for the Use of DHTs in Drug and Biological Product Development to guide the use of DHT-derived data in regulatory decision-making for drugs (hereinafter Framework ). The Framework highlights FDA’s DHT efforts including workshops and demonstration projects; engagement with stakeholders; establishment of internal processes to support the evaluation of DHTs for use in drug development; promotion of shared learning and consistency regarding DHT-based policy, procedure, and analytic tool development; and publication of guidance documents. In addition, FDA’s webpage DHTs for Drug Development (available at: https://www.fda.gov/science-research/science-and-research-special-topics/digital-health-technologies-dhts-drug-development) provides an overview of the ongoing DHT efforts, including demonstration projects. A variety of project types are welcomed under this NOFO, applicable to drugs and biologics (not devices). FDA is particularly interested in projects that evaluate the use of DHTs in drug development. Project Objectives The overarching goal of this notice of funding opportunity (NOFO) is to explore the role of DHTs (e.g., actigraphy, photography, environmental sensors) in the evaluation of new drugs. These projects may involve engagement with researchers from academia, the biopharmaceutical industry, patient groups, and other stakeholders. The objectives of these projects are to advance DHTs for clinical drug development, expand the ability to capture early manifestations of chronic diseases, determine outcomes in populations with unmet medical needs and enhance convenience for trial participants by allowing for remote data acquisition in clinical investigations. The scope includes, but is not limited to, projects that focus on: Comparing digital measurements to traditional measurements in clinical trials to evaluate drugs Developing and evaluating novel endpoints using DHTs to address unmet needs for drug clinical trials (e.g., use of environmental sensors to capture apnea in pediatric patients) Comparing metrics to evaluate continuous measurements (e.g., maximum activity and stamina) Capturing early manifestations of chronic diseases (e.g., dementia) through the use of DHTs

This funding opportunity supports clinical trials aimed at developing new therapies for rare neurodegenerative diseases, such as ALS, and is open to a wide range of eligible organizations, including universities and nonprofits.

This funding opportunity provides financial support to U.S.-based organizations, including universities, nonprofits, and businesses, to help outsourcing facilities produce critical medications that are in short supply and vulnerable to fraud.

The purpose of this funding opportunity announcement (FOA) is to fund innovative research that will strengthen and advance minority health and health equity objectives.Areas of interest include:Proposals that focus on advancing equity in clinical trials by supporting efforts to advance diversity in clinical trials, equitable data efforts by increasing data available on diverse groups including, but not limited to, ethnicity, race, age, disability and geography, and equity of voices by increasing understanding of diverse patient perspectives, preferences, and unmet needs.

The Tobacco Grant Program, administered by the Office of the Attorney General, California Department of Justice, aims to foster a healthier California by curtailing illegal cigarette and tobacco sales and marketing to minors. This highly competitive program, enabled by Proposition 56, allocates funds to applicants with robust enforcement capabilities. Funded agencies will focus on enforcing tobacco-related laws, conducting retailer and online inspections, and enhancing local coordination and education efforts.

The purpose of this funding opportunity is to support the research and development necessary to advance non-invasive (e.g., quantitative tomography-based) technologies, including the development of apparatus, methods, study designs, and methods of data analysis, to characterize and compare the rate and extent to which a topically applied drug becomes available at or near a site of action within the skin in vivo. The expectation is that the funded work will produce an accurate, sensitive and reproducible approach that rapidly measures the (relative) amount of drug present in the skin at a series of depths below the skin surface, which can be utilized to monitor the cutaneous pharmacokinetics (PK) of the drug at selected depths (e.g., in the epidermis) by repeated, serial measurements over time. The intent is to support the eventual development of an alternative, scientifically valid, in vivo cutaneous PK-based approach that can be used to efficiently demonstrate the bioequivalence (BE) of topical products.

The purpose of the funding opportunity is to expand and advance FDA's Office of Minority Health and Health Equity (OMHHE) work with stakeholders and partners for education, outreach, and public awareness activities on potential risks from skin lightening products containing hydroquinone and/or mercury.Applicants will research and propose innovative and community-based strategies and activities that have the potential to strengthen the science base for education and public health awareness on the use of and potential risks from over-the-counter (OTC) skin lightening products.

The FY24 BCRP Clinical Research Extension Award is designed to maximize the impact of previously funded breast cancer clinical studies by extending or expanding data collection, follow-up, and analysis. This mechanism directly addresses the loss of knowledge resulting from early trial termination, limited patient follow-up, or inadequate sample/data collection and analysis. The BCRP emphasizes the invaluable contributions of patient specimens and data, aiming to ensure that research maximizes the impact of these contributions toward saving lives and accelerating progress in ending breast cancer. Projects proposing to conduct new clinical trials will not be supported, focusing instead on leveraging existing clinical study infrastructure and data. The core impact goal of the award is to extend or affect the impact of a previously funded clinical trial or study, or to generate new impact toward ending breast cancer. Target beneficiaries include breast cancer patients whose contributions are utilized, and ultimately, active-duty Service Members, Veterans, military beneficiaries, and the American public who stand to benefit from advancements in breast cancer research. The program encourages collaborations between researchers at military/Veteran institutions and non-military institutions to leverage unique resources and access to diverse clinical populations, ensuring the research is relevant to the military community and the general public. Priorities and focuses for the proposed research, although not all-inclusive, include deeper molecular analysis of clinical samples, new correlative studies, biomarker validation, or continuing clinical follow-up of patients in open or completed trials. The research may be hypothesis-testing, -generating, or designed to create clinically annotated and molecularly characterized experimental platforms, such as patient-derived models. A required component is the involvement of two or more breast cancer consumer advocates—individuals diagnosed with breast cancer and active in advocacy organizations—who must provide objective input on the research design and its potential impact for individuals with, or at risk for, breast cancer. Innovation is not a required criterion for this award. Expected outcomes include generating meaningful hypotheses or supporting valid conclusions through statistically appropriate sample sizes and robust data analysis. Applicants must outline a data-sharing plan to ensure the scientific community has access to experimental platforms, molecular, and other data generated. The award encourages meaningful and productive partnerships, offering a Partnering PI Option with a higher funding limit ($6M vs. $5M for a single PI) to support collaborative efforts where both PIs bring distinct and critical expertise, reinforcing a strategic priority to foster team science in complex research questions. The CDMRP expects to allot approximately $18.6 million to fund about two applications.

The purpose of this Notice of Funding Opportunity (NOFO) is to solicit grant applications from neutral, independent institutions and/or organizations to support meetings (e.g., conferences, workgroups, roundtables) that convene a broad range of multiple stakeholders, including those with relevant expertise, to explore, research, and address issues related to medical products, policy, and surveillance methods and systems. Support includes, but is not limited to the design, planning, execution, synthesis, summary, and communication of findings from these forums to a broad range of organizations and individuals.

This grant provides funding to organizations in Texas that promote financial literacy and consumer credit education, helping communities improve their financial stability at little or no cost.

This funding opportunity provides $1 million to various organizations to develop and implement strategies for effectively sharing clinical practice guidelines, particularly in underserved communities, to improve healthcare quality and equity.

This funding opportunity supports a central hub for collaboration between the FDA and the generic drug industry, focusing on research and development of complex generics to improve access to safe and effective medications.

This funding opportunity provides financial support to local public agencies in California to enforce laws against the illegal sale and marketing of tobacco products to minors and youth.

This funding opportunity is designed to support organizations that provide financial education initiatives in Washington State, helping to improve financial literacy among residents.